Skip to content

Source filing unavailable

Q2 2020 · —
Revenue$0.00no prior Q2 2019 on fileno prior Q1 2020 on file
Net Income-$15.72Mno prior Q2 2019 on fileN/M vs Q1 2020
EPS Diluted-$2.90no prior Q2 2019 on fileN/M vs Q1 2020
Operating Income-$15,539,000—
Operating Cash Flowderived-$12,595,000—
Free Cash Flowderived-$14,843,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q2 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR